Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Investigational New Drugs
|
May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
Khobe Chandran, Christina Guo, Simon Pacey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2018
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Jonathan Welti, Adam Sharp, Wei Yuan, et al.
Cancer Discovery
|
May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno, Bora Gurel, Rita Pereira, et al.
Cancer Discovery
|
April 21, 2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Amy C Mandigo, Wei Yuan, Kexin Xu, et al.
European Urology
|
May 1, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
Adam Sharp, Jon C Welti, Maryou B K Lambros, et al.
Cancer Research
|
April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Crescens Tiu, Wing Yau, Diogo Silva, et al.
Cancer Research
|
November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate Cancer
Veronica Gil, Susana Miranda, Ruth Riisnaes, et al.
European Urology
|
November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Investigational New Drugs
|
May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
Khobe Chandran, Christina Guo, Simon Pacey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2018
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Jonathan Welti, Adam Sharp, Wei Yuan, et al.
Cancer Discovery
|
May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno, Bora Gurel, Rita Pereira, et al.
Cancer Discovery
|
April 21, 2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Amy C Mandigo, Wei Yuan, Kexin Xu, et al.
European Urology
|
May 1, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
Adam Sharp, Jon C Welti, Maryou B K Lambros, et al.
Cancer Research
|
April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Alec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma
Crescens Tiu, Wing Yau, Diogo Silva, et al.
Cancer Research
|
November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate Cancer
Veronica Gil, Susana Miranda, Ruth Riisnaes, et al.
European Urology
|
November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
Page
of 4